GlassScriptPhysician profile
Kathryn Gard
NPI 1487097606
$2,203.41
in general payments reported to CMS, 2019-2025
27 companies · $398 in 2025
The $398 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $46.33 · 2021: $104 · 2022: $343 · 2023: $437 · 2024: $515 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.02 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $251.02 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $224.75 | 2019-2025 | Aptima, Thinprep 2000 Processor, Affirm Prone Biopsy System |
| Pfizer INC. | $203.41 | 2022-2025 | |
| Abbvie INC. | $178.42 | 2019-2023 | |
| Organon LLC | $134.96 | 2022-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $134.40 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $133.77 | 2022-2025 | |
| Millicent US INC | $116.05 | 2020-2025 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $105.09 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $89.01 | 2021-2024 | Slynd |
| Baxter Healthcare | $75.54 | 2019-2024 | Tisseel |
| Therapeuticsmd, INC. | $73.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $57.01 | 2023-2024 | Keytruda, Gardasil 9 |
| Amag Pharmaceuticals, INC. | $55.74 | 2019-2020 | |
| Biogen, INC. | $53.87 | 2025 | Zurzuvae |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $53.37 | 2021-2023 | |
| Myovant Sciences INC. | $49.69 | 2021-2022 | |
| Coopersurgical, INC. | $39.40 | 2019-2022 | |
| Avion Pharmaceuticals | $29.21 | 2022-2023 | Balcoltra |
| Vertex Pharmaceuticals Incorporated | $26.32 | 2025 | |
| Minerva Surgical, INC | $21.90 | 2022 | |
| Glaxosmithkline, LLC. | $21.52 | 2024 | Arexvy, Shingrix |
| Duchesnay USA Incorporated | $18.42 | 2019 | |
| Lupin INC. | $17.31 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.96 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.62 | 2019 | |
| Meditrina | $9.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Gard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.